在患有的儿科患者中实现perampanel的初始治疗目标
Lingyan Yu1, Meng Chen1, Jieqiong Liu2
1Department of Pharmacy, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Frontiers in pharmacology
|November 30, 2023
概括
在中国的儿科患者中,Perampanel显示出良好的初始目标实现. 常规治疗药物监测可能不需要,除非同时使用酶诱导性抗药物.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 儿科神经学 儿科神经学
- 临床药房 临床药房
背景情况:
- 佩拉曼奈尔是一种抗药物 (AED),在儿科患者的血度可变.
- 优化perampanel剂量对于有效治疗儿童至关重要.
研究的目的:
- 评估在中国儿科患者中达到帕拉曼尼尔血度的初始目标.
- 为了确定影响这个人群中佩拉曼尼尔度达到的因素.
主要方法:
- 在2020年1月至2021年12月期间治疗的137名儿科患者的回顾性分析.
- 收集人口统计数据,剂量策略和治疗药物监测 (TDM) 结果.
- 统计分析以确定目标实现率和相关风险因素.
主要成果:
- 89.8%的儿科患者获得了适当的帕拉曼尼尔血度 (100-1,000 ng/mL).
- 同时使用酶诱导性AED是唯一不达到 (OR = 5.92) 的显著风险因素.
- 在perampanel度中观察到广泛的个体间变异 (60-1,560 mg/L).
结论:
- 在中国的儿科患者中,初始的帕拉曼尼尔目标达到值是令人满意的.
- 对大多数患者来说,对perampanel的常规治疗药物监测可能是不必要的.
- 推给儿科患者服用佩拉曼尼尔与酶诱导性AEDs同时服用TDM.
相关概念视频
Antiepileptic Drugs: Glutamate Antagonists
376
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
376
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
314
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
314
Antiepileptic Drugs: Potassium Channel Activators
186
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
186
Antiepileptic Drugs: GABAergic Pathway Potentiators
414
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
414


